Featured Research

from universities, journals, and other organizations

University Of Illinois At Chicago Tests Anti-Cancer Tablet

Date:
September 12, 1997
Source:
University Of Illinois At Chicago
Summary:
As the University of Illinois at Chicago's Institute for Tuberculosis Research celebrates its 50th anniversary, researchers here are moving forward to identify components of the tuberculosis vaccine, BCG, that are effective in the treatment of cancers when taken orally.

As the University of Illinois at Chicago's Institute for Tuberculosis Research celebrates its 50th anniversary, researchers here are moving forward to identify components of the tuberculosis vaccine, BCG, that are effective in the treatment of cancers when taken orally.

The institute first made headlines in 1950 when its renowned director, the late Dr. Sol Roy Rosenthal, developed what appeared to be a new substrain and superior form of BCG, called the Tice substrain (after his mentor). The Tice substrain was the only effective TB vaccine available in the United States, though other BCG vaccines have been used in Western Europe for decades.

With the decline of TB cases in the United States and a growing body of research showing BCG to be an effective stimulant of the immune system and anti-cancer agent, researchers at the Institute shifted the focus of their work. They began to extract and identify the components of BCG that are effective against cancer and tested those components in laboratory and animal studies.

The UIC institute's most recently published research offers promise for an effective non-surgical treatment of breast and other hormone-dependent cancers that would be delivered orally and fight cancer using the patient's own immune system. Researchers identified an orally active compound from BCG that suppressed a hormone-dependent, human breast-cancer cell line growing in mice without functioning immune systems.

BCG already is an established clinical treatment for bladder cancer, and tests also have shown it to be effective against colon and lung cancers. To work, BCG cells must have direct contact with tumor cells. Patients being treated with BCG for bladder cancer, therefore, must be injected with the vaccine. Injecting BCG close to the tumor, however, carries a risk. A blood vessel may be nicked and the living organism can grow in the patient.

The anti-cancer component of BCG identified by UIC researchers not only may be taken orally, but also may be produced inexpensively. Researchers estimate that a human dose could cost as little as $3. The compound developed at the Institute for Tuberculosis Research has the added benefit of having no unpleasant side-effects, such as the flu-like syndrome that accompanies immunization with the TB vaccine. Further investigation into the active BCG component and its mode of action is planned and will be necessary before the institute can begin human clinical testing.

(Editor: For more information, call Jody Oesterreicher, 312/996-8277; joest@uic.edu)


Story Source:

The above story is based on materials provided by University Of Illinois At Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University Of Illinois At Chicago. "University Of Illinois At Chicago Tests Anti-Cancer Tablet." ScienceDaily. ScienceDaily, 12 September 1997. <www.sciencedaily.com/releases/1997/09/970912150116.htm>.
University Of Illinois At Chicago. (1997, September 12). University Of Illinois At Chicago Tests Anti-Cancer Tablet. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/1997/09/970912150116.htm
University Of Illinois At Chicago. "University Of Illinois At Chicago Tests Anti-Cancer Tablet." ScienceDaily. www.sciencedaily.com/releases/1997/09/970912150116.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins